Has Lorenzo Gallon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $120,002 in general payments to Lorenzo Gallon, MD across 113 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lorenzo Gallon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lorenzo Gallon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lorenzo Gallon, MD

Nephrology · Chicago, ILNPI 1427093848

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $79,013 and has fallen 92.6% since, to $5,856 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$120,002in general payments, 2019–2025

Across 113 payments — averaging $1061.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$78K
Argenx US, Inc.$13K
Calliditas Therapeutics US Inc.$8K
Immucor, Inc.$5K
Gilead$5K
Mallinckrodt Enterprises LLC$4K
plus $5K from 5 others

$219,417in research payments, 2019–2025

Across 9 payments — averaging $24,380 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Veloxis Pharmaceuticals, Inc.$127K
Novartis$60K
E.r. Squibb & Sons, L.L.C.$32K

What the payments were for

Consulting fees$37,55031%
Speaking & faculty fees$68,28857%
Travel & lodging$11,91310%
Food & beverage$2,2522%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	88	$78,312
Argenx US, Inc.	5	$13,263
Calliditas Therapeutics US Inc.	4	$8,220
Immucor, Inc.	1	$5,400
Gilead	7	$5,146
Mallinckrodt Enterprises LLC	2	$4,285
Amgen	1	$2,075
Takeda Pharmaceuticals U.S.A., Inc.	1	$2,000
Baxter Healthcare	1	$862
GSK	1	$275
Sanofi-aventis U.S. LLC	2	$164

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,002 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois →

Medicare billing

Part B allowed, 2024

$9,386

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Envarsus XrTacrolimus	25	$33,593
Mycophenolate Mofetil	20	$1,211
Nifedipine ErNifedipine	28	$562
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	115	$525
Prednisone	58	$335
Calcitriol	22	$288
Carvedilol	35	$171
Tamsulosin Hcl	14	$132

Paid to pharmacies, not to this prescriber.

Other nephrology in Chicago

Myles WolfChicago$2.1M
Susan QuagginChicago$262K
Nicole StankusChicago$235K
Marco BonillaChicago$148K
Vikram AggarwalChicago$117K
Jay KoynerChicago$113K
Jose ArrudaChicago$107K
John FriedewaldChicago$93K
Casey GashtiChicago$74K
Amr YafiChicago$71K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →